Cryoport launches Temperature Controlled Logistics Consulting Division

In addition, the cryogenic logistics services provider began providing logistics solutions that support ProteoGenex Inc’s shipping of biological specimens.    Cryoport, Inc., a cryogenic logistics services provider, launched its Temperature Controlled Logistics Consulting Division to help life science companies create strategies for global cold chain logistics management, along with contingency options to protect their biological commodities, the company said.
   The new consulting division addresses the demand created by global advances in cellular based therapies, including immunotherapies, stem cells and CAR T-cells.
   “Cell-based immunotherapies are causing broad shifts and challenges for the life sciences industry, including how to obtain, properly store and transport the growing number of new, individualized, temperature sensitive therapies,” Cryoport said. “Improper temperature maintenance or temperature excursions during any portion of a logistics journey can adversely affect the viability of these biologically based commodities, quickly destroying tens of thousands to millions of dollars of irreplaceable life-saving material.”
   The division is headed by Tamie Joeckel, who recently joined Cryoport’s executive team as Sr. Vice President-Client Services. Ms. Joeckel has more than 25 years of pharmaceutical industry experience, having worked with a variety of companies including AmerisourceBergen, McKesson, PAREXEL and Dohmen Life Sciences.
   Overall, Cryoport currently supports 64 clinical trials in the regenerative medicine space and over 500 clients around the world by providing logistics solutions for biological materials.
   The company recently began providing cryogenic logistics solutions that support ProteoGenex, Inc’s shipping of global specimans.
   “Cryoport is working with ProteoGenex’s biological specimen business to make the transition from cold chain shipping using dry ice to Cryoport’s cryogenic logistics solutions, which virtually eliminates the risk of degradation during transport through the use of our dry vapor shippers,” Cryoport Chief Executive Officer Jerrell Shelton said.
   “Cryoport’s solutions offer a safer, more effective and consistent way to transport our biological specimens that will ultimately prevent degradation or loss of our product,” ProteoGenex Head of Operations Marina Prilutskaya said. “By utilizing Cryoport’s reusable shippers we will reduce our use of consumable dry ice shipping materials and many of our clients will save over 50 percent on shipping and handling costs.”